Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
MMWR. Morbidity and Mortality Weekly Report·
- DOI
- 10.15585/mmwr.mm7422a3
- PMID
- 40531798
- PMCID
- PMC12176103
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Centers for Disease Control MMWR Office
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The recommendations provide outbreak-specific vaccination guidance amid ongoing mpox transmission and substantial morbidity and mortality. Future need for the outbreak recommendation will be reassessed as the outbreak evolves.
Structured evidence summary
Research question
How should JYNNEOS vaccination be recommended for U.S. adults at risk for mpox during mpox outbreaks, including the multinational clade IIb outbreak?
Study design
The Advisory Committee on Immunization Practices reviewed a previously performed modified GRADE assessment of the 2-dose JYNNEOS series and Evidence to Recommendations frameworks addressing benefits, harms, target-population values, and preferences.
Population and setting
Persons aged at least 18 years at risk for mpox during U.S. mpox outbreaks, irrespective of clade, and during the multinational clade IIb outbreak.
Main findings
ACIP recommended JYNNEOS for adults at risk for mpox during an outbreak, regardless of clade. In 2023, it also recommended the vaccine for adults at risk of acquiring mpox during the multinational clade IIb outbreak; routine vaccination was not recommended for health care personnel during mpox outbreaks, including the ongoing clade IIb outbreak.
Public-health relevance
The recommendations provide outbreak-specific vaccination guidance amid ongoing mpox transmission and substantial morbidity and mortality. Future need for the outbreak recommendation will be reassessed as the outbreak evolves.
Important limitations
The summary is limited to the supplied single-article abstract and metadata, and the original paper is required for decision-grade interpretation.
GIDS interpretation
The article provides context for discovering mpox outbreak vaccination guidance and is classified under smallpox, monkeypox, the United States, outbreak investigation, transmission dynamics, and vaccination; it does not establish or confirm a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.